论文部分内容阅读
目的观察缬沙坦治疗前、后高血压合并糖尿病患者血清脂联素水平的变化。方法将120例患者分为缬沙坦组和非洛地平组。观察治疗前及治疗8周后血压、血糖、脂联素、胰岛素的变化。结果与治疗前相比,缬沙坦组与非洛地平组收缩压和舒张压均明显降低(P<0.01),缬沙坦组血清脂联素水平较治疗前明显升高(P<0.01),血糖、胰岛素抵抗较治疗前明显降低(P<0.01);非洛地平组治疗前后无明显改变(P>0.05)。结论缬沙坦在降压同时,显著升高了血清脂联素水平并改善胰岛素抵抗,显示其具有降压外良好的代谢效应。
Objective To observe the changes of serum adiponectin levels in patients with hypertension and before and after valsartan treatment. Methods 120 patients were divided into valsartan group and felodipine group. The changes of blood pressure, blood glucose, adiponectin and insulin before treatment and after 8 weeks of treatment were observed. Results Compared with those before treatment, the systolic and diastolic blood pressure in valsartan group and felodipine group were significantly decreased (P <0.01), and the levels of serum adiponectin in valsartan group were significantly higher than those before treatment (P <0.01) , Blood glucose and insulin resistance were significantly lower than those before treatment (P <0.01). There was no significant change in the felodipine group before and after treatment (P> 0.05). Conclusions Valsartan can significantly increase serum adiponectin level and improve insulin resistance at the same time of depressing blood pressure, which shows that it has a good metabolic effect outside of depressurization.